>2021 mAbTalk symposium: New Horizon of Antibody Drug Conjugate (ADC)
Antibody-drug conjugate (ADC) leverages the benefits of the high specificity from monoclonal antibody drugs and the high potency from small-molecule drugs to improve efficiency with reduced side-effects. Up to date, 11 ADC drugs have been approved by US FDA for marketing; 90 ADC drugs are in the clinical stage; and more than 200 are under discovery and preclinical development. Although ADC drugs have achieved impressive clinical outcome, there are still many challenges to overcome, such as toxic side effects, lack of biomarkers for screening patients, and development of drug resistance. Discovery of novel targets, conjugation technologies, and new payload modalities opens a new era of ADC therapeutics development.
At “New Horizon of Antibody-Drug Conjugate (ADC)” virtual symposium, speakers from biopharma industry and academia specializing in ADC-based drug development, will share their insights in diverse topics of ADC-based therapeutics, including discovery & new techniques, clinical development strategies, and CMC. Please come to enjoy the cutting-edge science and direct communications with ADC experts in the field.
Meet the speakers (partial):
05/22/2021 8 p.m. EST
Introduction to Chinese Antibody Society and mAbTalk
Daotian Fu, PhD, President, RemeGen
8:10 p.m. EST
Next-Generation Antibody-Drug Conjugates
Christoph Rader, PhD, Associate Dean, The Scripps Research Institute
8:40 p.m. EST
A novel ADC platform and the ADCs generated from the platform in the targeted treatment of cancer
Yongxin Zhao, PhD, President, DAC Biotech
9:10 p.m. EST
Novel Linker Technologies for Generating ADCs for Cancer Therapy
Kyoji Tsuchikama, PhD, Assistant Professor, The University of Texas Health Science Center at Houston
No abstract available
9:40 p.m. EST
Organizer, The Chinese Antibody Society
10:10 p.m. EST
Advancing ADCs for Transformative Cancer Therapies
Shan Jiang, PhD, Executive Director, Pharmaceutical Sciences, Seagen Inc.
10:40 p.m. EST
Challenges in the Clinical Development of Antibody Drug Conjugates
Min Liu, MD, Chief Medical Officer, TOT Biopharm
11:10 p.m. EST
ADC Product Quality Development and Control
Xinfang Li, PhD, President, MabPlex
This web search service is supported by Google Inc.